Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Ac-AKY-1189

Radiopharmaceutical · developed by Aktis Oncology

Phase 1 Most advanced trial
AKTS Developer
1 Registered trials

What is Ac-AKY-1189?

[225Ac]Ac-AKY-1189 is a therapeutic injection containing the radionuclide actinium-225 (225Ac). It is studied in urothelial carcinoma of the bladder, triple negative and hormone receptor positive breast cancer, non-small cell lung cancer, cervical adenocarcinoma, colorectal adenocarcinoma, and head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Aktis Oncology, Inc. (AKTS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07020117 Phase 1 Urothelial Carcinoma Bladder Recruiting AKTS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical AdenocarcinomaColorectal AdenocarcinomaHead and Neck CancerHormone Receptor Positive Breast AdenocarcinomaNon Small Cell Lung CancerTriple Negative Breast Cancer (TNBC)Urothelial Carcinoma Bladder

More from Aktis Oncology

Ac-AKY-2519 Phase 1 Cu-AKY-1189 Phase 1 Cu-AKY-2519 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AKTS page.

Follow AKTS, the company behind Ac-AKY-1189

See AKTS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AKTS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.